We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunoassays for Extrapulmonary Tuberculosis Need Improvement

By LabMedica International staff writers
Posted on 26 Aug 2013
The diagnosis of extrapulmonary tuberculosis (EPTB) is challenging as routine methods for diagnosis, such as smear for acid-fast bacilli (AFB) and culture of Mycobacterium tuberculosis on solid media, have poor sensitivity. More...


Nucleic acid amplification test and liquid culture methods are costly and required sophisticated infrastructure and therefore antibody based serodiagnosis tests for tuberculosis (TB) are used widely in developed and developing countries.

Scientists at the All India Institute of Medical Sciences (New Delhi, India) evaluated the diagnostic performance of commercially available enzyme-linked immunosorbent assay (ELISA) kit in the diagnosis of EPTB. They prospectively enrolled 354 patients, of whom 217 (61.2%) were EPTB patients and 137 (38.7%) were subjects with no suggestive TB, between 2007 and 2011. The mean age was 29.7 years for the EPTB patients and 31.2 years for the controls. Before culture inoculation, all samples were examined microscopically after Zeihl-Neelsen stain. All the isolates were confirmed as M. tuberculosis by species-specific in-house multiplex polymerase chain reaction (PCR) and phenotypic methods.

Three immunoglobulin based ELISA kits, PATHOZYME MYCO IgG, IgA, and IgM (Omega Diagnostics Limited; Alva, Scotland, UK) were used to check levels of antimycobacterial antibodies against two antigens in the serum of diseased and controls. The individual and overall sensitivity rates of IgM, IgA, and IgG assays were 29%, 24.4%, and 34.5%, respectively, while their specificities were 70.8%, 77.3%, and 68.6%, respectively. Not all TB patients produce antibodies against all antigenic epitopes in the cell walls of the tubercle bacilli, which infers on the inconsistency in specificity of antibody-based assays among different patient groups like gender, age, ethnicity, and geographical distribution.

The authors concluded that even though the specificity of the Pathozyme Myco IgA, IgM, and IgG was significantly better and acceptable as compared to pulmonary TB, the sensitivity of these kits was less than can be expected, and they did not recommend their use for diagnosis of EPTB. While a negative result by any one of these tests would be useful in helping to exclude disease in a population with a low prevalence of tuberculosis, a positive result may aid in clinical decision making when applied to symptomatic patients being evaluated for active tuberculosis. The study was published on August 1, 2013, in the Journal of Laboratory Physicians.

Related Links:

All India Institute of Medical Sciences
Omega Diagnostics Limited



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.